Literature DB >> 29348242

Anthracycline Cardiotoxicity: Worrisome Enough to Have You Quaking?

Daniel Bernstein1.   

Abstract

Entities:  

Keywords:  Editorials; RNA-binding protein; anthracyclines; cardiotoxicity; reactive oxygen species

Mesh：

Substances：

Year:  2018        PMID： 29348242      PMCID： PMC5776743          DOI： 10.1161/CIRCRESAHA.117.312395

Source DB:  PubMed          Journal:  Circ Res        ISSN： 0009-7330            Impact factor:   17.367


× No keyword cloud information.
  16 in total

1.  β2-adrenergic receptors mediate cardioprotection through crosstalk with mitochondrial cell death pathways.

Authors:  Giovanni Fajardo; Mingming Zhao; Gerald Berry; Lee-Jun Wong; Daria Mochly-Rosen; Daniel Bernstein
Journal:  J Mol Cell Cardiol       Date:  2011-07-02       Impact factor: 5.000

Review 2.  Anthracycline associated cardiotoxicity in survivors of childhood cancer.

Authors:  Steven E Lipshultz; Jorge A Alvarez; Rebecca E Scully
Journal:  Heart       Date:  2008-04       Impact factor: 5.994

Review 3.  New implications for the QUAKING RNA binding protein in human disease.

Authors:  Carol Anne Chénard; Stéphane Richard
Journal:  J Neurosci Res       Date:  2008-02-01       Impact factor: 4.164

4.  Characterization of circular RNAs in human, mouse and rat hearts.

Authors:  Stanislas Werfel; Stephan Nothjunge; Thomas Schwarzmayr; Tim-Matthias Strom; Thomas Meitinger; Stefan Engelhardt
Journal:  J Mol Cell Cardiol       Date:  2016-07-28       Impact factor: 5.000

5.  Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity.

Authors:  Paul W Burridge; Yong Fuga Li; Elena Matsa; Haodi Wu; Sang-Ging Ong; Arun Sharma; Alexandra Holmström; Alex C Chang; Michael J Coronado; Antje D Ebert; Joshua W Knowles; Melinda L Telli; Ronald M Witteles; Helen M Blau; Daniel Bernstein; Russ B Altman; Joseph C Wu
Journal:  Nat Med       Date:  2016-04-18       Impact factor: 53.440

6.  The RNA binding protein quaking regulates formation of circRNAs.

Authors:  Simon J Conn; Katherine A Pillman; John Toubia; Vanessa M Conn; Marika Salmanidis; Caroline A Phillips; Suraya Roslan; Andreas W Schreiber; Philip A Gregory; Gregory J Goodall
Journal:  Cell       Date:  2015-03-12       Impact factor: 41.582

Review 7.  Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity.

Authors:  Folefac Aminkeng; Colin J D Ross; Shahrad R Rassekh; Soomi Hwang; Michael J Rieder; Amit P Bhavsar; Anne Smith; Shubhayan Sanatani; Karen A Gelmon; Daniel Bernstein; Michael R Hayden; Ursula Amstutz; Bruce C Carleton
Journal:  Br J Clin Pharmacol       Date:  2016-06-30       Impact factor: 4.335

8.  Identification of the molecular basis of doxorubicin-induced cardiotoxicity.

Authors:  Sui Zhang; Xiaobing Liu; Tasneem Bawa-Khalfe; Long-Sheng Lu; Yi Lisa Lyu; Leroy F Liu; Edward T H Yeh
Journal:  Nat Med       Date:  2012-10-28       Impact factor: 53.440

9.  Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood.

Authors:  S E Lipshultz; S D Colan; R D Gelber; A R Perez-Atayde; S E Sallan; S P Sanders
Journal:  N Engl J Med       Date:  1991-03-21       Impact factor: 91.245

10.  Quaking Inhibits Doxorubicin-Mediated Cardiotoxicity Through Regulation of Cardiac Circular RNA Expression.

Authors:  Shashi Kumar Gupta; Ankita Garg; Christian Bär; Shambhabi Chatterjee; Ariana Foinquinos; Hendrik Milting; Katrin Streckfuß-Bömeke; Jan Fiedler; Thomas Thum
Journal:  Circ Res       Date:  2017-11-13       Impact factor: 17.367
View more
  8 in total

1.  Response by Bernstein to Letter Regarding Article, "Anthracycline Cardiotoxicity: Worrisome Enough to Have You Quaking?"

Authors:  Daniel Bernstein
Journal:  Circ Res       Date:  2018-03-30       Impact factor: 17.367

2.  Letter by Lipshultz Regarding Article, "Anthracycline Cardiotoxicity: Worrisome Enough to Have You Quaking?"

Authors:  Steven E Lipshultz
Journal:  Circ Res       Date:  2018-03-30       Impact factor: 17.367

Review 3.  Mitochondrial Sirtuins and Doxorubicin-induced Cardiotoxicity.

Authors:  Ling He; Fuxiang Liu; Juxiang Li
Journal:  Cardiovasc Toxicol       Date:  2021-01-12       Impact factor: 3.231

4.  Candesartan and carvedilol for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin.

Authors:  Myunhee Lee; Woo-Baek Chung; Ji-Eun Lee; Chan-Seok Park; Woo-Chan Park; Byung-Joo Song; Ho-Joong Youn
Journal:  Cancer Med       Date:  2021-05-16       Impact factor: 4.452

Review 5.  Mitochondria-Targeting Small Molecules Effectively Prevent Cardiotoxicity Induced by Doxorubicin.

Authors:  Wei Shi; Hongkuan Deng; Jianyong Zhang; Ying Zhang; Xiufang Zhang; Guozhen Cui
Journal:  Molecules       Date:  2018-06-19       Impact factor: 4.411

Review 6.  The Role of Flavonoids as a Cardioprotective Strategy against Doxorubicin-Induced Cardiotoxicity: A Review.

Authors:  Rony Abdi Syahputra; Urip Harahap; Aminah Dalimunthe; M Pandapotan Nasution; Denny Satria
Journal:  Molecules       Date:  2022-02-15       Impact factor: 4.411

Review 7.  Cardio-Oncology Rehabilitation-Present and Future Perspectives.

Authors:  Boaz Elad; Manhal Habib; Oren Caspi
Journal:  Life (Basel)       Date:  2022-07-07

Review 8.  Anthracycline-induced cardiotoxicity: mechanisms of action, incidence, risk factors, prevention, and treatment.

Authors:  Yehia Saleh; Ola Abdelkarim; Khader Herzallah; George S Abela
Journal:  Heart Fail Rev       Date:  2021-09       Impact factor: 4.214
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.